AbbVie Scraps $55B Shire Inversion After Treasury Crackdown

U.S. drugmaker AbbVie Inc. pulled the plug Thursday on its record-setting $55 billion plans to merge with British rival Shire PLC in a controversial inversion deal, a stunning reversal it blamed...

Already a subscriber? Click here to view full article